Baidu
map

Cancer Discov:英国女科学家Nature之后再发白血病治疗重磅研究

2016-09-17 佚名 生物谷

最近来自英国格拉斯哥大学的科学家们在慢性髓系白血病治疗方面又取得重大进展,他们找到新的药物组合可以杀死超过90%的慢性髓系白血病干细胞。相关研究结果发表在国际学术期刊Cancer Discovery上。正常的造血干细胞发生癌变会导致慢性髓系白血病的发生,白血病干细胞会产生大量白血病细胞,如果不能得到治疗就会产生致命后果。现在慢性髓系白血病的治疗主要使用酪氨酸激酶抑制剂,但是仅接受这种治疗无法达到治


最近来自英国格拉斯哥大学的科学家们在慢性髓系白血病治疗方面又取得重大进展,他们找到新的药物组合可以杀死超过90%的慢性髓系白血病干细胞。相关研究结果发表在国际学术期刊Cancer Discovery上。

正常的造血干细胞发生癌变会导致慢性髓系白血病的发生,白血病干细胞会产生大量白血病细胞,如果不能得到治疗就会产生致命后果。现在慢性髓系白血病的治疗主要使用酪氨酸激酶抑制剂,但是仅接受这种治疗无法达到治愈疾病的效果,只能将疾病的发展控制在比较低的水平。因此许多病人需要终生维持酪氨酸激酶抑制剂治疗,但是这类药物非常昂贵,同时可能引起严重的副作用。

格拉斯哥大学的研究人员一直在寻找杀死慢性髓系白血病干细胞的方法,最近他们发现了一种新药物有望通过杀死慢性髓系白血病干细胞彻底治愈慢性髓系白血病,研究人员表示这种药物通过抑制EZH2的活性发挥作用。之前有研究证明EZH2能够促进多种癌细胞的存活,但是在慢性髓系白血病中没有得到研究。

文章第一作者Mary Scott表示:“我们的目标是将这种药物推向临床试验,对慢性髓系白血病病人进行治疗。目前使用EZH2抑制剂治疗其他血液癌症的临床试验已经得到一些初步结果。这种药片形式的药物非常安全同时副作用很小,非常适于慢性髓系白血病的临床治疗。”

文章作者Tessa Holyoake教授曾在今年6月份的Nature杂志上发表一项研究成果,报道了一个完全不同的药物组合可以高度有效地靶向慢性髓系白血病干细胞。

Holyoake教授说:“这篇文章以及之前Nature文章的成果表明我们一直在坚持不懈地开发新方法,寻找杀死慢性髓系白血病干细胞的新药物。”

领域内专家表示,这项研究会促进药物开发,通过靶向癌症干细胞彻底治愈这种恶性疾病。众所周知癌症复发之后再进行治疗会变得更加困难,病人的生存几率更低,这项研究找到了一种新方法可以靶向杀死那些在治疗后仍然存在并可能导致疾病复发的细胞,希望可以尽快开展临床试验验证这种治疗方法的有效性和安全性。

原始出处

Scott MT1, Korfi K1, Saffrey P2, Hopcroft LE3, Kinstrie R2, Pellicano F3, Guenther C1, Gallipoli P3, Cruz M2, Dunn K3, Jorgensen HG3, Cassels JE3, Hamilton A3, Crossan A2, Sinclair A3, Holyoake TL4, Vetrie D5.Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.Cancer Discov.2016


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881326, encodeId=b40b188132600, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 02 07:11:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012129, encodeId=9a2b201212971, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Dec 06 04:11:00 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136779, encodeId=142a136e7921, content=学习了,很有借鉴意义的治疗思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160928/IMG57EAA257515D23353.jpg, createdBy=70ae1638193, createdName=axzpiglet, createdTime=Wed Sep 28 02:41:32 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136242, encodeId=844b136242c4, content=学习了,很受益,谢谢分享,继续关注中!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Sep 27 17:10:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548892, encodeId=4c18154889210, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573860, encodeId=24d215e3860df, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587801, encodeId=7ba9158e80179, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=)]
    2016-10-02 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881326, encodeId=b40b188132600, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 02 07:11:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012129, encodeId=9a2b201212971, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Dec 06 04:11:00 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136779, encodeId=142a136e7921, content=学习了,很有借鉴意义的治疗思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160928/IMG57EAA257515D23353.jpg, createdBy=70ae1638193, createdName=axzpiglet, createdTime=Wed Sep 28 02:41:32 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136242, encodeId=844b136242c4, content=学习了,很受益,谢谢分享,继续关注中!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Sep 27 17:10:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548892, encodeId=4c18154889210, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573860, encodeId=24d215e3860df, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587801, encodeId=7ba9158e80179, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881326, encodeId=b40b188132600, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 02 07:11:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012129, encodeId=9a2b201212971, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Dec 06 04:11:00 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136779, encodeId=142a136e7921, content=学习了,很有借鉴意义的治疗思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160928/IMG57EAA257515D23353.jpg, createdBy=70ae1638193, createdName=axzpiglet, createdTime=Wed Sep 28 02:41:32 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136242, encodeId=844b136242c4, content=学习了,很受益,谢谢分享,继续关注中!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Sep 27 17:10:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548892, encodeId=4c18154889210, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573860, encodeId=24d215e3860df, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587801, encodeId=7ba9158e80179, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=)]
    2016-09-28 axzpiglet

    学习了,很有借鉴意义的治疗思路

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1881326, encodeId=b40b188132600, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 02 07:11:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012129, encodeId=9a2b201212971, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Dec 06 04:11:00 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136779, encodeId=142a136e7921, content=学习了,很有借鉴意义的治疗思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160928/IMG57EAA257515D23353.jpg, createdBy=70ae1638193, createdName=axzpiglet, createdTime=Wed Sep 28 02:41:32 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136242, encodeId=844b136242c4, content=学习了,很受益,谢谢分享,继续关注中!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Sep 27 17:10:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548892, encodeId=4c18154889210, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573860, encodeId=24d215e3860df, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587801, encodeId=7ba9158e80179, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=)]
    2016-09-27 童小孩

    学习了,很受益,谢谢分享,继续关注中!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1881326, encodeId=b40b188132600, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 02 07:11:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012129, encodeId=9a2b201212971, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Dec 06 04:11:00 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136779, encodeId=142a136e7921, content=学习了,很有借鉴意义的治疗思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160928/IMG57EAA257515D23353.jpg, createdBy=70ae1638193, createdName=axzpiglet, createdTime=Wed Sep 28 02:41:32 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136242, encodeId=844b136242c4, content=学习了,很受益,谢谢分享,继续关注中!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Sep 27 17:10:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548892, encodeId=4c18154889210, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573860, encodeId=24d215e3860df, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587801, encodeId=7ba9158e80179, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=)]
    2016-09-19 xxxx1054
  6. [GetPortalCommentsPageByObjectIdResponse(id=1881326, encodeId=b40b188132600, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 02 07:11:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012129, encodeId=9a2b201212971, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Dec 06 04:11:00 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136779, encodeId=142a136e7921, content=学习了,很有借鉴意义的治疗思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160928/IMG57EAA257515D23353.jpg, createdBy=70ae1638193, createdName=axzpiglet, createdTime=Wed Sep 28 02:41:32 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136242, encodeId=844b136242c4, content=学习了,很受益,谢谢分享,继续关注中!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Sep 27 17:10:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548892, encodeId=4c18154889210, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573860, encodeId=24d215e3860df, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587801, encodeId=7ba9158e80179, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1881326, encodeId=b40b188132600, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Oct 02 07:11:00 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012129, encodeId=9a2b201212971, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Dec 06 04:11:00 CST 2016, time=2016-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136779, encodeId=142a136e7921, content=学习了,很有借鉴意义的治疗思路, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160928/IMG57EAA257515D23353.jpg, createdBy=70ae1638193, createdName=axzpiglet, createdTime=Wed Sep 28 02:41:32 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=136242, encodeId=844b136242c4, content=学习了,很受益,谢谢分享,继续关注中!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Sep 27 17:10:07 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548892, encodeId=4c18154889210, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573860, encodeId=24d215e3860df, content=<a href='/topic/show?id=af0a44e03a4' target=_blank style='color:#2F92EE;'>#女科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44703, encryptionId=af0a44e03a4, topicName=女科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38cb15960013, createdName=zhty5342, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587801, encodeId=7ba9158e80179, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Sep 19 13:11:00 CST 2016, time=2016-09-19, status=1, ipAttribution=)]
    2016-09-19 yankaienglish

相关资讯

Lancet:X光CT等辐射是否致癌?

导语:著名医学杂志《柳叶刀》发表了一项调查结果:反复或长期的低剂量辐射能增加急性白血病的死亡率X线、CT等放射性的医学检查能否导致癌症,一直都没有明确的科学研究进行证实。最近世界著名医学杂志《柳叶刀》发表了一项大规模流行病学调查结果,证明反复或长期的低剂量辐射能增加急性白血病的死亡率。那么,是不是说这种放射性的检查已经不安全了呢?患者接受这样的检查真的会患上癌症吗?这篇论文中显示,除了放疗,人们暴

CA:谁说白血病患儿就一定要孤孤单单“与世隔绝”?

最近的一项研究表明,对于接受强化化疗治疗的儿童患者,限制社交、宠物和饮食,不会影响其感染性并发症的发生率。 先前有证据表明,抗感染药物和粒细胞生长因子可减少化疗患者的感染风险。但是,饮食限制(限制新鲜水果和蔬菜)、社交限制的有效性尚缺乏证据。基于这些“限制”可能会影响患者的生活质量,因此研究人员决定进行研究,探究这些限制性措施是否值得。 AML-BFM 2004试验:时间:2004年3

PNAS:维生素C也能治疗白血病?

维生素C缺乏症时常出现于癌症患者,往往会增加治疗的难度。如今,已有研究显示,维生素C的缺乏可能确实会降低某一类癌症药物的有效性。同时,基于这一发现的临床试验也已启动,以测试维生素C对于部分恶性血液肿瘤治疗的辅助效果。最近,来自美国Van Andel研究所和丹麦Rigshospitalet医院等机构的科学家们在体外实验中发现,维生素C可显着增强一种表观遗传药物5-aza-CdR的抗肿瘤效果。两者联用

第4个适应症!诺华抗癌药Arzerra获FDA批准治疗复发性慢性淋巴细胞白血病(CLL)

瑞士制药巨头诺华(Novartis)与合作伙伴Genmab联合开发的抗体药物Arzerra(ofatumumab)近日在美国监管方面传来喜讯。美国食品和药物管理局(FDA)已批准Arzerra联合氟达拉滨(fludarabine,F)和环磷酰胺(cyclophosphamide,C)用于复发性慢性淋巴细胞白血病(CLL)患者的治疗。这也是Arzerra在美国获批的第4个CLL适应症。 此次批准,

中国慢性髓性白血病诊断与治疗指南(2016年版)

慢性髓性白血病(CML)是骨髓造血干细胞克隆性增殖形成的恶性肿瘤,占成人白血病的15%,全球年发病率为1.6~2/10万。1986至1988年在我国22个省(市、自治区)46个调查点进行的全国白血病发病情况调查显示CML的年发病率为0.36/10万。此后国内几个地区的流行病学调查显示CML的年发病率为0.39~0.55/10万。中国CML患者较西方国家更为年轻化,国内几个地区的流行病学调查显示

NEJM:利用脐带血治疗白血病显神效

日前,一项刊登在国际杂志New England Journal of Medicine的题为“Cord-Blood Transplantation in Patients with Minimal Residual Disease”的研究报告中,来自福瑞德哈金森肿瘤研究中心的研究人员通过研究表示,脐带血或许可以作为治疗成人和儿童白血病的优选方案,甚至在有些病例治疗过程中脐带血治疗还能够带来较好的结

Baidu
map
Baidu
map
Baidu
map